RALEIGH, NC and QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with U.S. Senator Kay Hagan (D-NC) and U.S. Congressman David Price (D-NC), are holding an official groundbreaking ceremony this morning for its U.S. plant-based commercial grade vaccine facility in Research Triangle Park, North Carolina. Medicago U.S.A. also announced the appointment of Mike Wanner as Vice President of U.S. Operations.
With today's groundbreaking ceremony, Medicago U.S.A. officially commenced the construction of its cGMP facility in Research Triangle Park (RTP), North Carolina. This VLP plant-based vaccine facility will include a fully automated greenhouse and a state of the art extraction and purification unit. The facility is targeted to produce 10 million doses of pandemic influenza vaccine per month. On an annual basis, the facility would have production capacity of 40 million doses of seasonal Influenza vaccine or 120 million doses of pandemic influenza vaccine.
"Thanks to the efforts and experience of our partners Alexandria Real Estate Equities and BE&K Building Group as well as our employees at Medicago, we are confident that this fast-track project will be delivered on time," said Andy Sheldon, President and CEO of Medicago. "North Carolina and RTP is a great place to build our business due to the excellent workforce, training programs and quality of life."
"We are very pleased to be working with Alexandria Real Estate Equities and with Medicago who is bringing this unique, rapid and cost-effective vaccine technology to North Carolina and to the Research Triangle Park," stated Joseph M. Raimondi, Project Executive of BE&K Building Group.
Mr. Wanner joins
|SOURCE Medicago Inc.|
Copyright©2010 PR Newswire.
All rights reserved